Response to monotherapy with EGFR-TKIs is dependent on the presence of activating EGFR mutations, such as exon 19 deletions or L858R mutations, present in 16.6% of lung adenocarcinoma patients (10). The gene discussed is EGFR; the disease is lung adenocarcinoma.